IDEA Pharma | From R&D to RxD’s Post

Another strong performance for AstraZeneca who continue to thrive in the pharma innovation and invention space, ranking 7th on the Innovation Index and 3rd on the Invention Index. They achieved significant regulatory milestones, including three first NME approvals, 17 NMEs in late-stage development, and 123 NME or major LCM projects in Phase 2 or 3. Key approvals include among others: Airsupra (albuterol/budesonide), an as-needed treatment to reduce risk of asthma exacerbations; Truqap (capivasertib), a first-in-class AKT inhibitor for certain breast cancer indications with one or more biomarker alterations; and Wainua (eplontersen), the only approved self-administered auto-injector for the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. See the full analysis at - www.ideapharma.com/pii #pharmaceutical #innovation #PIII2024

2024 Invention Index | IDEA Pharma

2024 Invention Index | IDEA Pharma

ideapharma.com

To view or add a comment, sign in

Explore topics